Lp-PLA2: A New Target for Statin Therapy

Overview

Journal Curr Atheroscler Rep

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2010 Apr 29

PMID 20425268

Citations 10

Authors

Lynne T Braun

Michael H Davidson

Affiliations

Soon will be listed here.

Abstract

Inflammation plays an important role in atherogenesis and plaque vulnerability. Inflammatory-type markers have been evaluated for their association with atherosclerotic vascular disease and their ability to improve cardiovascular disease (CVD) risk stratification. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a vascular-specific inflammatory enzyme that increases the risk of CVD events and stroke approximately twofold. A consensus panel recently recommended the measurement of Lp-PLA(2) in moderate-risk and high-risk patients for improved risk stratification and modification of low-density lipoprotein target levels. Lipid-lowering agents, particularly statins, lower Lp-PLA(2) mass and activity; therefore, Lp-PLA(2) may represent an important target of lipid-lowering therapy for reducing the inflammatory nature of atherosclerosis and plaque vulnerability. It is unknown whether lowering inflammatory markers such as Lp-PLA(2) will have a direct benefit on CVD events and mortality. A large morbidity and mortality trial was recently initiated to evaluate the long-term safety and efficacy of darapladib, an Lp-PLA(2) antagonist, in patients with high-risk coronary heart disease.

Citing Articles

Lipid-Derived Biomarkers as Therapeutic Targets for Chronic Coronary Syndrome and Ischemic Stroke: An Updated Narrative Review.

Schreiner T, Ignat B, Grosu C, Costache A, Leon M, Mitu F Medicina (Kaunas). 2024; 60(4).

PMID: 38674207 PMC: 11052465. DOI: 10.3390/medicina60040561.

Lipoprotein-associated phospholipase A2 predicts cardiovascular death in patients on maintenance hemodialysis: a 7-year prospective cohort study.

Lin L, Teng J, Shi Y, Xie Q, Shen B, Xiang F Lipids Health Dis. 2024; 23(1):15.

PMID: 38216940 PMC: 10785463. DOI: 10.1186/s12944-023-01991-0.

The Phospholipase A2 Superfamily: Structure, Isozymes, Catalysis, Physiologic and Pathologic Roles.

Khan S, Ilies M Int J Mol Sci. 2023; 24(2).

PMID: 36674864 PMC: 9862071. DOI: 10.3390/ijms24021353.

Negative correlation between early recovery and lipoprotein-associated phospholipase A2 levels after intravenous thrombolysis.

Li Y, Wang W, Yang H, Guo W, Feng J, Yang D J Int Med Res. 2022; 50(4):3000605221093303.

PMID: 35441552 PMC: 9047848. DOI: 10.1177/03000605221093303.

Cardiovascular Disease, Statins, and HIV.

Eckard A, Meissner E, Singh I, McComsey G J Infect Dis. 2016; 214 Suppl 2:S83-92.

PMID: 27625435 PMC: 5021243. DOI: 10.1093/infdis/jiw288.

References

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

Gorelick P . Lipoprotein-associated phospholipase A2 and risk of stroke. Am J Cardiol. 2008; 101(12A):34F-40F. DOI: 10.1016/j.amjcard.2008.04.017. View

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-39. DOI: 10.1161/01.CIR.0000133317.49796.0E. View

Davidson M, Corson M, Alberts M, Anderson J, Gorelick P, Jones P . Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008; 101(12A):51F-57F. DOI: 10.1016/j.amjcard.2008.04.019. View

Davidson M . Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation. 2005; 111(18):2280-1. DOI: 10.1161/01.CIR.0000167560.93138.E7. View

Wilensky R, Shi Y, Mohler 3rd E, Hamamdzic D, Burgert M, Li J . Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008; 14(10):1059-66. PMC: 2885134. DOI: 10.1038/nm.1870. View

Anderson J . Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol. 2008; 101(12A):23F-33F. DOI: 10.1016/j.amjcard.2008.04.015. View

Ballantyne C, Hoogeveen R, Bang H, Coresh J, Folsom A, Chambless L . Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005; 165(21):2479-84. DOI: 10.1001/archinte.165.21.2479. View

Lerman A, McConnell J . Lipoprotein-associated phospholipase A2: a risk marker or a risk factor?. Am J Cardiol. 2008; 101(12A):11F-22F. DOI: 10.1016/j.amjcard.2008.04.014. View

10.

Pearson T, Mensah G, Alexander R, Anderson J, Cannon 3rd R, Criqui M . Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107(3):499-511. DOI: 10.1161/01.cir.0000052939.59093.45. View

11.

Schaefer E, McNamara J, Asztalos B, Tayler T, Daly J, Gleason J . Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol. 2005; 95(9):1025-32. DOI: 10.1016/j.amjcard.2005.01.023. View

12.

Serruys P, Garcia-Garcia H, Buszman P, Erne P, Verheye S, Aschermann M . Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008; 118(11):1172-82. DOI: 10.1161/CIRCULATIONAHA.108.771899. View

13.

Saougos V, Tambaki A, Kalogirou M, Kostapanos M, Gazi I, Wolfert R . Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol. 2007; 27(10):2236-43. DOI: 10.1161/ATVBAHA.107.147280. View

14.

Mohler 3rd E, Ballantyne C, Davidson M, Hanefeld M, Ruilope L, Johnson J . The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized,.... J Am Coll Cardiol. 2008; 51(17):1632-41. DOI: 10.1016/j.jacc.2007.11.079. View

15.

Corson M, Jones P, Davidson M . Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008; 101(12A):41F-50F. DOI: 10.1016/j.amjcard.2008.04.018. View

16.

Cook N, Buring J, Ridker P . The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006; 145(1):21-9. DOI: 10.7326/0003-4819-145-1-200607040-00128. View

17.

Ridker P, Rifai N, Rose L, Buring J, Cook N . Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347(20):1557-65. DOI: 10.1056/NEJMoa021993. View

18.

Muhlestein J, May H, Jensen J, Horne B, Lanman R, Lavasani F . The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol. 2006; 48(2):396-401. DOI: 10.1016/j.jacc.2006.05.009. View

19.

Ballantyne C, Hoogeveen R, Bang H, Coresh J, Folsom A, Heiss G . Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004; 109(7):837-42. DOI: 10.1161/01.CIR.0000116763.91992.F1. View

20.

Koenig W, Twardella D, Brenner H, Rothenbacher D . Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006; 26(7):1586-93. DOI: 10.1161/01.ATV.0000222983.73369.c8. View